VIDEO3:00
Martin Tallman, Chief of the Leukemia Service at Memorial Sloan Kettering Cancer Center, discusses a new clinical trial combining arsenic trioxide with all-transretinoic acid (ATRA) for the treatment of patients with high-risk acute promyelocytic leukemia.